Matches in Wikidata for { <http://www.wikidata.org/entity/Q95319993> ?p ?o ?g. }
Showing items 1 to 62 of
62
with 100 items per page.
- Q95319993 description "2020 മെയ് 15 നു പ്രസിദ്ധീകരിച്ച ശാസ്ത്ര ലേഖനം" @default.
- Q95319993 description "article scientifique publié en 2020" @default.
- Q95319993 description "artykuł naukowy opublikowany 15 maja 2020" @default.
- Q95319993 description "artículu científicu espublizáu en mayu de 2020" @default.
- Q95319993 description "bài báo khoa học" @default.
- Q95319993 description "im Mai 2020 veröffentlichter wissenschaftlicher Artikel" @default.
- Q95319993 description "scientific article published on 15 May 2020" @default.
- Q95319993 description "wetenschappelijk artikel" @default.
- Q95319993 description "наукова стаття, опублікована 15 травня 2020" @default.
- Q95319993 name "Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status" @default.
- Q95319993 name "Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status" @default.
- Q95319993 type Item @default.
- Q95319993 label "Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status" @default.
- Q95319993 label "Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status" @default.
- Q95319993 prefLabel "Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status" @default.
- Q95319993 prefLabel "Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status" @default.
- Q95319993 P1433 Q95319993-FE203923-4AD6-4F8A-A85A-B34B439D0F5C @default.
- Q95319993 P1476 Q95319993-6CD6CC45-DFBF-4B5C-9F62-AC300E8FFA9A @default.
- Q95319993 P2093 Q95319993-27A6A457-0E4A-4961-BDCA-81CA0E6C5BF8 @default.
- Q95319993 P2093 Q95319993-2FF31D9C-5DB5-410D-9547-790C3E98150C @default.
- Q95319993 P2093 Q95319993-3D04E636-083C-4965-A15B-5DD6379C1A04 @default.
- Q95319993 P2093 Q95319993-416785BA-8357-463C-9058-AF4D74405CC7 @default.
- Q95319993 P2093 Q95319993-5098DFBE-92D5-40C1-89CE-3D716A9680F8 @default.
- Q95319993 P2093 Q95319993-51CB6158-DE8D-49FF-87BB-CB14B9DFA130 @default.
- Q95319993 P2093 Q95319993-57B3EB90-0FC2-44DA-96FD-5D9DCE2789CE @default.
- Q95319993 P2093 Q95319993-92AF2E4C-B9A5-4CDA-B196-BE2BBAA1AA74 @default.
- Q95319993 P2093 Q95319993-AD076554-6DBA-4ABA-9100-B96A771D7950 @default.
- Q95319993 P2093 Q95319993-B92AFB88-E448-406F-B037-2DB680460C1D @default.
- Q95319993 P2093 Q95319993-B9993260-BD0A-4DC3-AC6F-12AFC10EC4AE @default.
- Q95319993 P2093 Q95319993-CF41BFDD-3A2C-43ED-87E0-5E594550E25E @default.
- Q95319993 P2093 Q95319993-DF565B8E-BA97-4B78-A1EE-9D20966B981E @default.
- Q95319993 P2093 Q95319993-E17658B2-4A7F-4EB9-B10B-7F078C298A39 @default.
- Q95319993 P31 Q95319993-59ECB2FD-0DE8-4C71-9C8B-05AE9C745D73 @default.
- Q95319993 P356 Q95319993-6C243B0C-CB7F-435E-85E8-ED86FE814064 @default.
- Q95319993 P577 Q95319993-BC3BCDB2-73A5-4874-AFF5-94FAD77B5150 @default.
- Q95319993 P698 Q95319993-2B238FC8-F350-4969-9F05-B7BD2D613B8F @default.
- Q95319993 P921 Q95319993-DB20D25A-FE1A-4B73-A91C-0B4AA7E91CCE @default.
- Q95319993 P932 Q95319993-158EF336-6255-41D3-B34D-3DC229EDEDE9 @default.
- Q95319993 P356 J.EUO.2020.02.009 @default.
- Q95319993 P698 32423837 @default.
- Q95319993 P1433 Q63882907 @default.
- Q95319993 P1476 "Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status" @default.
- Q95319993 P2093 "Arjun V Balar" @default.
- Q95319993 P2093 "Daniel Castellano" @default.
- Q95319993 P2093 "Dean F Bajorin" @default.
- Q95319993 P2093 "Elizabeth R Plimack" @default.
- Q95319993 P2093 "Jacqueline Vuky" @default.
- Q95319993 P2093 "James L Godwin" @default.
- Q95319993 P2093 "Joaquim Bellmunt" @default.
- Q95319993 P2093 "Misoo C Ellison" @default.
- Q95319993 P2093 "Noah M Hahn" @default.
- Q95319993 P2093 "Peter H O'Donnell" @default.
- Q95319993 P2093 "Petros Grivas" @default.
- Q95319993 P2093 "Ronald de Wit" @default.
- Q95319993 P2093 "Tara L Frenkl" @default.
- Q95319993 P2093 "Thomas Powles" @default.
- Q95319993 P31 Q13442814 @default.
- Q95319993 P356 "10.1016/J.EUO.2020.02.009" @default.
- Q95319993 P577 "2020-05-15T00:00:00Z" @default.
- Q95319993 P698 "32423837" @default.
- Q95319993 P921 Q13896859 @default.
- Q95319993 P932 "8246631" @default.